<?xml version="1.0" encoding="UTF-8"?>
<p id="Par47">In 1998, a live, oral, tetravalent rhesus–human reassortment rotavirus vaccine (RotaShield, Wyeth-Ayerst Laboratories, St. David, PA) was licensed and recommended for routine immunization of infants in the USA; it was voluntarily withdrawn from the market in 1999 due to its association with intestinal intussusception noted in postmarketing surveillance [
 <xref ref-type="bibr" rid="CR179">179</xref>–
 <xref ref-type="bibr" rid="CR181">181</xref>]. Two additional Rotavirus vaccines have been studied (RotaTeq, Merck &amp; Company, Whitehouse Station, NJ; Rotarix, GlaxoSmithKline Biologicals, Rixensart, Belgium). Both vaccines are oral and contain live virus, and are thus contraindicated in highly immunocompromised patients. Fecal virus shedding has been noted with both vaccines, with transmission of vaccine-associated virus to household members noted with Rotarix [
 <xref ref-type="bibr" rid="CR181">181</xref>].
</p>
